Beam Therapeutic Rg
BEAM
USD
STOCK MARKET:
NMS
Open
 
...
Large gap with delayed quotes
Last quote
06/17/2026 - 21:35:42
Bid
06/17/2026 - 21:36:28
Bid
Volume
Ask
06/17/2026 - 21:36:28
Ask
Volume
32.26
+1.27 ( +4.10% )
32.23
100
32.34
100
More information
Analysis by TheScreener
16.06.2026
Evaluation Slightly negative  
Interest Strong  
Sensibility High  
Analysis date: 16.06.2026
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 26.05.2026.
Interest
  Strong
Three stars since 16.06.2026.
Earnings Rev Trend
  0.10
 
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 12.06.2026 at a price of 29.03.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Positive
 
The dividend-adjusted forty day technical trend is positive since 26.05.2026.
4wk Rel Perf
  9.57%
 
The four-week dividend-adjusted overperformance versus SP500 is 9.57%.
Sensibility
  High
High, no change over 1 year.
Bear Market Factor
  Middle
On average, the stock is likely to decline with the index.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 4.98%.
Mkt Cap in $bn
  3.20
With a market capitalization between $2 & $8bn, BEAM THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  -2.26
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
  -7.37
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  -16.65%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
  16
Over the last seven weeks, an average of 16 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  212
For 1% of index variation, the stock varies on average by 2.12%.
Correlation
  0.33
Stock movements are strongly independent of index variations.
Value at Risk
  20.11
The value at risk is estimated at USD 20.11. The risk is therefore 64.89%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  23.07.2021